Charles E. Binkley, MD, Michael S. Politz, MA, and Brian P. Green, PhD
If the safe-and-effective standard for judging devices’ potential as therapy or enhancement is inadequate, one might wonder whether BCI regulation should be overseen by the FDA.
AMA J Ethics. 2021;23(9):E745-749. doi:
10.1001/amajethics.2021.745.
Dr Charles Binkley joins Ethics Talk to discuss his article, coauthored with Michael Politz and Dr Brian Green: "Who, If Not the FDA, Should Regulate Implantable Brain-Computer Interface Devices?"
One patient’s experience of life-encompassing iatrogenic harm from being institutionalized emphasizes Italy’s comparative success, relative to the United States, in recovering from decades of deinstitutionalization policy.
AMA J Ethics. 2022;24(8):E795-803. doi:
10.1001/amajethics.2022.795.
Joel A. DeLisa, MD, MS and Jacob Jay Lindenthal, PhD, DrPH
Research on experiences of practicing physicians who have disabilities could help medical schools counsel applicants and increase enrollment among students with disabilities. This can ultimately improve care for patients with disabilities.
AMA J Ethics. 2016;18(10):1003-1009. doi:
10.1001/journalofethics.2016.18.10.stas1-1610.
Pamela B. Teaster, PhD, MA, MS and Al O. Giwa, LLB, MD, MBA, MBE
Since ageism contributes to global mental health inequity among older people, responding to their needs should be a clinical, ethical, and policy priority.
AMA J Ethics. 2023;25(10):E765-770. doi:
10.1001/amajethics.2023.765.
Patients with dementia need social supports and opportunities and acceptance of their disability in order to feel hopeful despite their functional decline.
AMA J Ethics. 2017;19(7):649-655. doi:
10.1001/journalofethics.2017.19.7.ecas2-1707.